查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1316800

结合疫苗市场：按类型（单价、多价）、适应症（白喉/百日咳、流感、脑膜炎双球菌）、病原体、最终用户 - 2023-2030 年全球预测

Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球结合疫苗市场将大幅成长396.7亿美元，年复合成长率为10.79%，到2030年将达到814.2亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球结合疫苗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1. 结合疫苗的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球结合疫苗市场的阻碍因素与影响有哪些？

3. 在预测期内，全球结合疫苗市场需要投资哪些产品/细分市场/应用/领域？

4.全球结合疫苗市场的竞争策略是什么？

5. 全球结合疫苗市场的技术趋势和法律规范是什么？

6.全球结合疫苗市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球结合疫苗市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和免疫抑制的盛行率增加
      • 癌症治疗疫苗的采用增加
      • 世卫组织增加疫苗接种推广计划
    • 抑制因素
      • 偏远地区获得疫苗的机会很少
    • 机会
      • 政府努力提高人们对感染疾病的认识
      • 新型结合疫苗生产技术的进展
    • 任务
      • 结合疫苗製备过程的复杂性
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章结合疫苗市场：依类型

  • 单价
  • 多价的

第7章结合疫苗市场适应症

  • 白喉和百日咳
  • 流感
  • 脑膜炎奈瑟菌
  • 肺炎球菌

第8章以病原体类型分類的结合疫苗市场

  • 细菌结合疫苗
  • 联合结合疫苗
  • 病毒结合疫苗

第9章结合疫苗市场：依最终用户分类

  • 成人
  • 孩子

第10章美洲结合疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第11章亚太结合疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章欧洲/中东/非洲结合疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第13章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第14章上市公司名单

第15章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-433AB1DC2903

The Global Conjugate Vaccine Market is forecasted to grow significantly, with a projected USD 39.67 billion in 2023 at a CAGR of 10.79% and expected to reach a staggering USD 81.42 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Conjugate Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Conjugate Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Monovalent and Multivalent. The Monovalent is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal. The Pneumococcal is projected to witness significant market share during forecast period.

Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine. The Bacterial Conjugate Vaccine is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Adults and Children. The Adults is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Conjugate Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Conjugate Vaccine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Conjugate Vaccine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Conjugate Vaccine Market?

4. What is the competitive strategic window for opportunities in the Global Conjugate Vaccine Market?

5. What are the technology trends and regulatory frameworks in the Global Conjugate Vaccine Market?

6. What is the market share of the leading vendors in the Global Conjugate Vaccine Market?

7. What modes and strategic moves are considered suitable for entering the Global Conjugate Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Conjugate Vaccine Market, by Type, 2022 vs 2030
  • 4.3. Conjugate Vaccine Market, by Indication, 2022 vs 2030
  • 4.4. Conjugate Vaccine Market, by Pathogen Type, 2022 vs 2030
  • 4.5. Conjugate Vaccine Market, by End-User, 2022 vs 2030
  • 4.6. Conjugate Vaccine Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
      • 5.1.1.2. Rising adoption of cancer therapeutic vaccines
      • 5.1.1.3. Rising number programs to promote vaccination by WHO
    • 5.1.2. Restraints
      • 5.1.2.1. Low accessibility to vaccines in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives spreading awareness about infectious diseases
      • 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of production procedure of conjugate vaccine
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Conjugate Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent
  • 6.3. Multivalent

7. Conjugate Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Diphtheria & Pertussis
  • 7.3. Influenza
  • 7.4. Meningococcal
  • 7.5. Pneumococcal

8. Conjugate Vaccine Market, by Pathogen Type

  • 8.1. Introduction
  • 8.2. Bacterial Conjugate Vaccine
  • 8.3. Combination Conjugate Vaccine
  • 8.4. Viral Conjugate Vaccine

9. Conjugate Vaccine Market, by End-User

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Children

10. Americas Conjugate Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Conjugate Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Conjugate Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 6. CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 8. CONJUGATE VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. CONJUGATE VACCINE MARKET DYNAMICS
  • FIGURE 10. CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. CONJUGATE VACCINE MARKET SIZE, BY ADULTS , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 188. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 189. CONJUGATE VACCINE MARKET LICENSE & PRICING